Literature DB >> 2391063

Fine specificity of human antibody response to the PreS1 domain of hepatitis B virus.

A Alberti1, D Cavalletto, L Chemello, F Belussi, G Fattovich, P Pontisso, G Milanesi, A Ruol.   

Abstract

The preS1 domain of hepatitis B virus envelope proteins contains a site of attachment to the hepatocyte membrane that has been shown to evoke virus-neutralizing antibodies. Using synthetic peptides, we have examined kinetics and specificity of the anti-body response to preS1 during acute and chronic HBV infection. Antibodies against two continuous B cell epitopes, p (21-32) and p (32-47), which overlap with the virus receptor for hepatocytes, were detected in 17 (28%) and 28 (47%) patients, respectively, of 60 patients who were tested during acute hepatitis B. Serial testing demonstrated these anti-preS1 specificities in more than 50% of patients who became virus free. By contrast, five patients with chronic evolution of hepatitis B and 61 of 66 patients with an established chronic HBV infection were negative, independent of serological profile and liver disease activity. Fifteen (22.7%) patients with chronic hepatitis B were positive for antibody to the C-terminus p (94-117) preS1 sequence that, unlike the acute-phase anti-(21-32) and anti-(32-47) reactivities, did not behave as a virus-precipitating antibody. Acute-phase sera were found to also contain virus-precipitating antibodies directed against conformational preS1 epitopes. These results indicate that the preS1 site, which contains the binding activity for the hepatocyte membrane, elicits an early antibody response during acute hepatitis B. A defect in such antibody repertoire may participate in the chronicity process as a result of continuing reinfection of hepatocytes by circulating virions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2391063     DOI: 10.1002/hep.1840120204

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

Review 1.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins.

Authors:  Wei-Guo Hu; Jun Wei; Heng-Chuan Xia; Xin-Xiu Yang; Feng Li; Guang-Di Li; Yuan Wang; Zu-Chuan Zhang
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

Review 3.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

4.  Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Authors:  D C Whitacre; C J Peters; C Sureau; K Nio; F Li; L Su; J E Jones; M Isogawa; M Sallberg; L Frelin; D L Peterson; D R Milich
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

5.  PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen.

Authors:  Ulla B Hellström; Kazimierz Madalinski; Staffan Pe Sylvan
Journal:  Virol J       Date:  2009-01-20       Impact factor: 4.099

6.  Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.

Authors:  Carolin Cornelius; Katrin Schöneweis; Fanny Georgi; Milena Weber; Verena Niederberger; Petra Zieglmayer; Katarzyna Niespodziana; Michael Trauner; Harald Hofer; Stephan Urban; Rudolf Valenta
Journal:  EBioMedicine       Date:  2016-08-08       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.